HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms.

HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody.

The phase 1 clinical trial in China is a multicenter, open-label study, which will assess HMPL-A83’s safety, tolerability, pharmacokinetics, and preliminary efficacy in in the advanced cancerous tumors.

According to HUTCHMED (China), the primary endpoints of the HMPL-A83 phase 1 trial are dose-limiting toxicity (DLT), safety, tolerability, recommended phase II dose (RP2D), as well as maximum tolerated dose (MTD).

The secondary endpoints of the early-stage trial are pharmacodynamics, pharmacokinetics, immunogenicity, and preliminary efficacy profile.

Dr Weiguo Su — HUTCHMED (China) CEO and Chief Scientific Officer said: “HMPL-A83 marks a new chapter in our large molecule and immunotherapy exploration.

“It is our thirteenth oncology drug candidate to emerge from our innovative in-house discovery platform and it has significant potential to offer new combination therapy opportunities with our existing small molecule portfolio. This approach forms a key part of our multi-pronged strategy to treat cancer and immunological diseases and we are very excited to advance HMPL-A83’s development.”

  cancer, China, Dr Weiguo Su, HMPL-A83, HUTCHMED (China), malignant neoplasms, Neoplasm, Oncology, Tumor